scholarly journals Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

2018 ◽  
Vol Volume 13 ◽  
pp. 3923-3936 ◽  
Author(s):  
Kai Michael Beeh ◽  
Anne-Marie Kirsten ◽  
Ana-Maria Tanase ◽  
Alexia Richard ◽  
Weihua Cao ◽  
...  
Keyword(s):  
Lung Function ◽  
Fluticasone Propionate ◽  
Phase Ii ◽  
Mometasone Furoate ◽  
Double Blind ◽  
Salmeterol Xinafoate ◽  
Severe Copd

scholarly journals Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations

2015 ◽  
Vol 109 (7) ◽  
pp. 870-881 ◽  
Author(s):  
James F. Donohue ◽  
Sally Worsley ◽  
Chang-Qing Zhu ◽  
Liz Hardaker ◽  
Alison Church
Keyword(s):  
Lung Function ◽  
Fluticasone Propionate ◽  
Severe Copd

scholarly journals Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial

2020 ◽  
pp. 00425-2020
Author(s):  
Jutta Beier ◽  
Henrik Watz ◽  
Zuzana Diamant ◽  
Jens M. Hohlfeld ◽  
Dave Singh ◽  
...  
Keyword(s):  
Lung Function ◽  
Randomised Trial ◽  
Mometasone Furoate ◽  
Fixed Dose ◽  
Night Time ◽  
Double Blind ◽  
Once Daily ◽  
Moderate Asthma ◽  
Asthma Patients ◽  
Long Acting

Once-daily asthma treatment should prevent night-time deterioration, irrespective of the time of dosing. IND/GLY/MF, a fixed-dose combination of inhaled indacaterol acetate (IND, long-acting β2-agonist), glycopyrronium bromide (GLY, long-acting muscarinic antagonist), and mometasone furoate (MF, inhaled corticosteroid [ICS]) delivered by Breezhaler®, is indicated in adult asthma patients inadequately controlled on LABA/ICS.A randomised, double-blind, placebo-controlled, three-period, crossover, phase II study was performed to investigate the bronchodilator effect of IND/GLY/MF (150/50/80 μg) dosed am and pm versus placebo in patients with mild-moderate asthma. The primary endpoint was weighted mean forced expiratory volume in 1 s (FEV1) over 24 h following 14 days of IND/GLY/MF dosed am and pm versus placebo. Secondary endpoints included the effect of dosing time on peak expiratory flow (PEF) and safety/tolerability.Of 37 randomised patients (age 18–72 years, 21 male, 16 female) 34 completed all three treatment periods. At screening, median (range) pre-bronchodilator FEV1 was 75.8% (60–96). Patients were using stable low- (83.8%) or medium-dose (16.2%) ICS. Morning and evening dosing of IND/GLY/MF improved FEV1 (AUC0–24h) by 610 mL (90% CI: 538, 681) and 615 mL (90% CI: 544, 687), respectively, versus placebo. Mean PEF over 14 days increased by 70.7 L·min−1 (90% CI: 60.5, 80.9) following am dosing, and by 59.7 L·min−1 (90% CI: 49.5, 69.9) following pm dosing of IND/GLY/MF versus placebo. IND/GLY/MF demonstrated a safety profile comparable with placebo.Once-daily inhaled IND/GLY/MF was well tolerated and provided sustained lung function improvements over 24 h, irrespective of am or pm dosing, in patients with mild-moderate asthma.

Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma

2020 ◽  
Author(s):  
K Chapman ◽  
H Watz ◽  
J Beier ◽  
D Singh ◽  
J Hohlfeld ◽  
...  
Keyword(s):  
Lung Function ◽  
Mometasone Furoate
Sign in / Sign up

Export Citation Format

Share Document